醫思健康(02138.HK)斥1,575萬元收購大埔獸醫醫院75%股權
醫思健康(02138.HK)公布,以總代價1,575萬元收購一家在大埔經營獸醫醫院的目標公司的75%已發行股本。受制於協議之條款,賣方向集團保證目標公司於完成收購後共三年之累計經審計之稅後溢利將不少於 1,050萬元。
根據由賣方提供的截止2021年10月31日止七個月之未經審計財務資料,目標公司於該期間的稅後溢利約為260萬元。目前,目標公司於大埔經營一間獸醫醫院,擁有4名註冊獸醫。
公司認為,收購事項將使目標公司業務與集團業務產生協同效應;使集團業務組合多樣化;提供新收入來源;及為現有業務提供新客源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.